ESMO 2026 has ended. This guide stays up as the record of who was there. Next: ESMO 2027, Sep 17–21, 2027 in Barcelona

Societies and non-profits at ESMO 2026

Oct 23–27, 2026 Madrid, Spain ~37k attendees Website

79 societies and non-profits are at ESMO 2026 — 100 presentations on the program and 13 with a booth in the exhibit hall. Most represented: Netherlands Comprehensive Cancer Organisation (IKNL) (4 on the program), European Organisation for Research and Treatment of Cancer (EORTC) (4 on the program), Cancer Research UK (4 on the program). As of Nov 2, 2026.

All 1,879 organizations at ESMO 2026 →

Tumour type
Top represented
Showing 1–8 of 79 organizations
OrganizationESMO 2026 Attendance
Society & non-profit
Independent Dutch cancer knowledge institute in Utrecht that runs the Netherlands Cancer Registry.
Poster
Sat Oct 24
12:00–12:45
Abstract
Sun Oct 25
16:35–16:40
3085RO - Potentially inappropriate end-of-life care and its association with bereaved relatives' quality of life
Rapid oral: Supportive and palliative care
Nursing & supportive care
Society & non-profitExhibitor
Independent non-profit that runs international academic cancer clinical trials across Europe.
Booth
Exhibiting at Booth S1041
Poster
Fri Oct 23
13:00–15:00
Coverage of treatment-related toxicities by EORTC QLQ-C30 and QLQ-H&N43 in head and neck cancer
ePoster session 8
Sarcoma, CNS, head & neck and rare cancersNursing & supportive care
Poster
Fri Oct 23
13:00–15:00
Poster
Sat Oct 24
12:00–12:45
Cancer Research UK
Manchester, United Kingdom
Society & non-profit
A cancer research and support charity based in the United Kingdom.
Poster
Fri Oct 23
13:00–15:00
Digital patient reporting of toxicities in phase 1/2a cancer clinical trials
ePoster session 20
Nursing & supportive care
Poster
Fri Oct 23
15:15–16:00
TARGET: A precision medicine programme for matching experimental therapy using circulating tumour DNA
Friday Poster Display session 3
Biomarkers & precision oncology
Poster
Fri Oct 23
15:15–16:00
Tie2 is the first vascular response biomarker for VEGFi
Friday Poster Display session 2
Gastrointestinal cancersGynaecological cancersBiomarkers & precision oncology
Abstract
Sun Oct 25
09:19–09:24
World Health Organization
Geneva, Switzerland
Society & non-profit
United Nations agency for international public health, based in Geneva, Switzerland.
Talk
Fri Oct 23
16:35–16:55
Modelling economic impact to deliver population health impact
The exorbitant costs of cancer care: What can we do?
Talk
Sat Oct 24
10:35–10:55
Building and evaluating a sustainable cancer priority setting system in
ESMO-WHO-IARC collaboration in global cancer control
Talk
Sat Oct 24
10:55–11:15
Cancer workforce crisis: Building solutions
ESMO-WHO-IARC collaboration in global cancer control
Chair
Sat Oct 24
14:45–16:15
Rapid oral: Policy
with Brazilian National Cancer Institute (INCA), Mahatma Gandhi Medical College and Hospital
Abstract
Sat Oct 24
15:52–16:07
Chair
Sun Oct 25
08:30–10:00
Talk
Sun Oct 25
08:30–08:35
Introduction
Cancer care in humanitarian settings
Society & non-profit
Nonprofit academic cooperative group that designs and runs cancer clinical trials across Latin America, based in Porto Alegre, Brazil.
Poster
Sat Oct 24
12:00–12:45
Talk
Sat Oct 24
16:30–16:45
How can we incorporate combination strategies in early drug development?
Novel concepts for metastatic breast cancer: Looking to the future
Breast cancerBiomarkers & precision oncology
Chair
Sat Oct 24
16:30–18:00
Novel concepts for metastatic breast cancer: Looking to the future
with Peter MacCallum Cancer Centre
Breast cancerBiomarkers & precision oncology
Satellite
Sat Oct 24
18:55–19:05
Interactive panel discussion
Eli Lilly and Company - Navigating the Therapeutic Crossroads in HR+ HER2- Breast Cancer: Defining Your Next Clinical Decision · with Evangelische Kliniken Essen-Mitte, Dana-Farber Cancer Institute
Breast cancer
Satellite
Sat Oct 24
19:05–19:20
Rethinking Metastatic Breast Cancer: Endocrine Sensitivity, Biomarkers, and the Role of
Eli Lilly and Company - Navigating the Therapeutic Crossroads in HR+ HER2- Breast Cancer: Defining Your Next Clinical Decision
Breast cancer
Satellite
Sat Oct 24
19:20–19:30
Interactive panel discussion
Eli Lilly and Company - Navigating the Therapeutic Crossroads in HR+ HER2- Breast Cancer: Defining Your Next Clinical Decision · with Evangelische Kliniken Essen-Mitte, Dana-Farber Cancer Institute
Breast cancer
Satellite
Sat Oct 24
19:40–19:50
Interactive panel discussion
Eli Lilly and Company - Navigating the Therapeutic Crossroads in HR+ HER2- Breast Cancer: Defining Your Next Clinical Decision · with Evangelische Kliniken Essen-Mitte, Dana-Farber Cancer Institute
Breast cancer
Talk
Sun Oct 25
10:15–10:45
Metastatic breast cancer: Case presentation & Discussion
ESMO Clinical Practice Guidelines 2 · with Sestre milosrdnice University Hospital Centre
Breast cancerGenitourinary cancers
Satellite
Sun Oct 25
18:30–18:35
Welcome and Introduction
Gilead and Kite Oncology - The ADC Evolution in Breast and Gynaecologic Cancers: Foundation, Advancement, Future Directions
Breast cancerGynaecological cancers
Satellite
Sun Oct 25
18:35–19:00
Clinical Foundation: Building and Broadening the Role of ADCs in Metastatic Breast Cancer
Gilead and Kite Oncology - The ADC Evolution in Breast and Gynaecologic Cancers: Foundation, Advancement, Future Directions
Breast cancerGynaecological cancers
Satellite
Sun Oct 25
19:45–20:00
Connecting Experience, Potential, and Future Frontiers: Panel discussion and audience Q&A
Gilead and Kite Oncology - The ADC Evolution in Breast and Gynaecologic Cancers: Foundation, Advancement, Future Directions · with University of California San Diego, University Hospitals Leuven
Breast cancerGynaecological cancers
Society & non-profit
Cancer research agency of the World Health Organization in Lyon, France, studying the causes of cancer and how to prevent it.
Chair
Sat Oct 24
10:15–11:45
ESMO-WHO-IARC collaboration in global cancer control
with Centre Léon Bérard
Talk
Sat Oct 24
10:15–10:35
Global perspectives from WHO-IARC
ESMO-WHO-IARC collaboration in global cancer control
Talk
Sat Oct 24
11:15–11:35
How to set priorities for research
ESMO-WHO-IARC collaboration in global cancer control
Talk
Sun Oct 25
09:20–09:35
Cancer surveillance and resilience
Cancer care in humanitarian settings
Cancer Patients Europe
Brussels, Belgium
Society & non-profit
Patient advocacy organisation in Brussels representing cancer patients, survivors and carers in European health policy.
Satellite
Sat Oct 24
12:40–12:50
Current experience of patients receiving SC IO
MSD - Oncology Nursing Perspectives on Subcutaneous Immunotherapy: Practical Considerations for Patient Care
Nursing & supportive care
Talk
Sun Oct 25
09:45–09:55
CN35 - Nutrition in cancer care: Closing the gap between awareness and action
Supportive care and symptom management
Nursing & supportive care
Society & non-profit
European umbrella organisation of patient groups for colorectal and other digestive cancers, based in Brussels, Belgium.
Chair
Sun Oct 25
16:30–18:00
Talk
Sun Oct 25
17:15–17:30
Patient testimony
Extending life, realizing potential: Bridging innovation and implementation in cancer care
Talk
Mon Oct 26
15:25–15:45
The patient perspective on the use of CPG in the cancer continuum
How can the use of ESMO's Clinical Practice Guidelines (CPG) help drive standards of care?

Explore the full ESMO 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Madrid. Leave your work email and we’ll be in touch.

Privacy

Download the full ESMO 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Find buyers from societies and non-profits

Tell us what you sell and we’ll find the people at these societies and non-profits most likely to buy it.

  • Who to contact
  • Their contact info
  • What to say
  • Free, no sign-up

Browse ESMO 2026 by

Exhibit hall

Not affiliated with or endorsed by the European Society for Medical Oncology. Submit a correction